Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC

被引:2
作者
Shen, Zi-Qing [1 ]
Feng, Kun-Peng [1 ]
Fang, Zi-Yao [1 ]
Xia, Tian [1 ]
Pan, Shu [1 ]
Ding, Cheng [1 ]
Xu, Chun [1 ]
Ju, Sheng [1 ]
Chen, Jun [1 ]
Li, Chang [1 ]
Zhao, Jun [1 ]
机构
[1] Soochow Univ, Med Coll, Affiliated Hosp 1, Dept Thorac Surg, Suzhou 215000, Peoples R China
关键词
Adjuvant chemotherapy; Early stage; Non-small cell lung cancer; High risk; CELL LUNG-CANCER; VISCERAL PLEURAL INVASION; LYMPH-NODE COUNT; SQUAMOUS-CELL; PROGNOSTIC-FACTORS; AMERICAN-COLLEGE; PLUS CISPLATIN; ADENOCARCINOMA; CLASSIFICATION; RECURRENCE;
D O I
10.1186/s13019-023-02457-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe use of adjuvant chemotherapy (ACT) in completely resected stage IB NSCLC is still controversial. This study aims to investigate the efficacy of ACT in pathological stage IB non-small cell lung cancer (NSCLC) with high risk factors.MethodsPatients with pT2aN0M0 stage IB NSCLC who underwent complete resection from 2013 to 2017 were retrospectively analyzed. Univariate and multivariable logistic regression analysis was used to assess potential independent risk factors associated with poor prognosis. To compare survival between patients who received ACT and those who did not.ResultsIn univariate and multivariate analyses, adenocarcinomas with predominantly micropapillary (MIP) and solid patterns (SOL), poorly differentiated squamous cell carcinoma (SCC), number of lymph nodes dissected less than 16 and tumor size larger than 36 mm were identified as high-risk factors for recurrence. In patients with high risk factors for recurrence, ACT resulted in significantly longer DFS (HR, 0.4689, 95%CI, 1.193-3.818; p = 0.0108) and OS (HR, 0.4696, 95%CI, 0.6578-6.895; p = 0.2073), although OS failed to reach statistically significance. After propensity score matching (PSM), 67 pairs of patients were 1:1 matched in the two groups and all baseline characteristics were well balanced. The results also demonstrated that ACT was associated with improved DFS (HR, 0.4776, 95%CI, 0.9779-4.484; p = 0.0440) while OS was not significantly different (92.5% vs. 91.0%; HR, 0.6167, 95%CI, 0.1688-2.038; p = 0.7458). In patients with low-risk factors for recurrence, DFS (HR, 0.4831, 95%CI, 0.03025-7.715; p = 0.6068) and OS (HR, 0.969, 95%CI, 0.08364-11.21; p = 0.9794) was not significantly different between those who received ACT and those who did not.ConclusionIn patients with completely resected stage IB NSCLC, ACT can improve survival in patients with high risk for recurrence. Further large multicenter studies are needed to confirm these findings.
引用
收藏
页数:10
相关论文
共 52 条
[1]  
al BEMSLTGe, 2013, J Thorac Oncology: Official Publication Int Association Study Lung Cancer, V8, P201
[2]   Adjuvant chemotherapy for resected early-stage non-small cell lung cancer [J].
Burdett, Sarah ;
Pignon, Jean Pierre ;
Tierney, Jayne ;
Tribodet, Helene ;
Stewart, Lesley ;
Le Pechoux, Cecile ;
Auperin, Anne ;
Le Chevalier, Thierry ;
Stephens, Richard J. ;
Arriagada, Rodrigo ;
Higgins, Julian P. T. ;
Johnson, David H. ;
Van Meerbeeck, Jan ;
Parmar, Mahesh K. B. ;
Souhami, Robert L. ;
Bergman, Bengt ;
Douillard, Jean-Yves ;
Dunant, Ariane ;
Endo, Chiaki ;
Girling, David ;
Kato, Harubumi ;
Keller, Steven M. ;
Kimura, Hideki ;
Knuuttila, Aija ;
Kodama, Ken ;
Komaki, Ritsuko ;
Kris, Mark G. ;
Lad, Thomas ;
Mineo, Tommaso ;
Piantadosi, Steven ;
Rosell, Rafael ;
Scagliotti, Giorgio ;
Seymour, Lesley K. ;
Shepherd, Frances A. ;
Sylvester, Richard ;
Tada, Hirohito ;
Tanaka, Fumihiro ;
Torri, Valter ;
Waller, David ;
Liang, Ying .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (03)
[3]   Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10 [J].
Butts, Charles A. ;
Ding, Keyue ;
Seymour, Lesley ;
Twumasi-Ankrah, Philip ;
Graham, Barbara ;
Gandara, David ;
Johnson, David H. ;
Kesler, Kenneth A. ;
Green, Mark ;
Vincent, Mark ;
Cormier, Yvon ;
Goss, Glenwood ;
Findlay, Brian ;
Johnston, Michael ;
Tsao, Ming-Sound ;
Shepherd, Frances A. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :29-34
[4]   Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma [J].
Cao, Shuhui ;
Teng, Jiajun ;
Xu, Jianlin ;
Han, Baohui ;
Zhong, Hua .
THORACIC CANCER, 2019, 10 (02) :249-255
[5]   Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer [J].
Dai, Jie ;
Liu, Ming ;
Yang, Yang ;
Li, Qiuyuan ;
Song, Nan ;
Rocco, Gaetano ;
Sihoe, Alan D. L. ;
Gonzalez-Rivas, Diego ;
Suen, Hon Chi ;
He, Wenxin ;
Duan, Liang ;
Fan, Jiang ;
Zhao, Deping ;
Wang, Haifeng ;
Zhu, Yuming ;
Chen, Chang ;
Diasio, Robert B. ;
Jiang, Gening ;
Yang, Ping ;
Zhang, Peng .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) :1277-1285
[6]   Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy Results of the Randomized, Prospective American College of Surgeons Oncology Group Z0030 Trial [J].
Darling, Gail E. ;
Allen, Mark S. ;
Decker, Paul A. ;
Ballman, Karla ;
Malthaner, Richard A. ;
Inculet, Richard I. ;
Jones, David R. ;
McKenna, Robert J. ;
Landreneau, Rodney J. ;
Putnam, Joe B., Jr. .
CHEST, 2011, 139 (05) :1124-1129
[7]   Does Lymph Node Count Influence Survival in Surgically Resected Non-Small Cell Lung Cancer? [J].
David, Elizabeth A. ;
Cooke, David T. ;
Chen, Yingjia ;
Nijar, Kieranjeet ;
Canter, Robert J. ;
Cress, Rosemary D. .
ANNALS OF THORACIC SURGERY, 2017, 103 (01) :226-235
[8]   Reframing recalcitrance for small-cell lung cancer [J].
Blackhall, F. H. .
ANNALS OF ONCOLOGY, 2021, 32 (07) :829-830
[9]   Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial [J].
Douillard, Jean-Yves ;
Rosell, Rafael ;
De Lena, Mario ;
Carpagnano, Francesco ;
Ramlau, Rodryg ;
Gonzales-Larriba, Jose Luis ;
Grodzki, Tornasz ;
Pereira, Jose Rodrigues ;
Le Groumellec, Alain ;
Lorusso, Vito ;
Clary, Claude ;
Torres, Antonio J. ;
Dahabreh, Jabrail ;
Souquet, Pierre-Jean ;
Astudillo, Julio ;
Fournel, Pierre ;
Artal-Cortes, Angel ;
Jassem, Jacek ;
Koubkova, Leona ;
His, Patricia ;
Riggi, Marcella ;
Hurteloup, Patrick .
LANCET ONCOLOGY, 2006, 7 (09) :719-727
[10]   Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment [J].
Duma, Narjust ;
Santana-Davila, Rafael ;
Molina, Julian R. .
MAYO CLINIC PROCEEDINGS, 2019, 94 (08) :1623-1640